title: Actively personalized cancer vaccines--the step into clinical application.
abstract: Cancer vaccine development enters a new phase of innovation based on the development of modern sequencing technologies and novel RNA-based synthetic drug formats which enable the analysis and therapeutic targeting of every patient's tumor genome. By applying and combining these innovations, we have brought the concept of "actively personalized cancer vaccines" to clinical testing. Synthetic RNA is used as the drug format, allowing affordable, individual "on demand" manufacturing of tumor-optimized vaccines.
authors: B P
authors: BP
authors: Kloke
authors: S
authors: S
authors: Kreiter
authors: M
authors: M
authors: Vormehr
authors: M
authors: M
authors: Diken
authors: A N
authors: AN
authors: Kuhn
authors: U
authors: U
authors: Sahin
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control*; D012334:RNA, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D012334:RNA, Neoplasm